Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

Completed · Phase 1

Conditions studied: HIV Infection

In brief

The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.

Key facts

Study ID

NCT00352066

Run by

Avexa

People needed

18

Starts

2006-07-01

Expected to finish

2006-08-01

Last updated by the study team

2011-06-23

Who can join

Age: 18 and older, up to 40. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• healthy males 18-40 years old
• non-smokers
• no clinically significant medical history

You may not qualify if…

• current or relevant previous medical history of significance
• hepatitis B, hepatitis C, or HIV positive
• current use of prescription or OTC medications
• use of illicit substances or alcohol (>14 drinks/week)

Where it is running

• Jasper Clinic Inc — Kalamazoo, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.